Individualized Medication Guidance for Gynecologic Cancer CapitalBio

According to the latest statistics on new cancer among Chinese women, cervical cancer and ovarian cancer rank among the top ten new cases of female cancer (about 110,000 and 60,000 respectively). With the widespread clinical application of poly(ADP-ribose) polymerase (PARP) inhibitors, progression-free survival (PFS) in ovarian cancer patients has been significantly prolonged. At present, the biomarkers related to PARP inhibitor treatment mainly include BRCA1/2 gene mutation, HRR gene mutation, etc., and some studies have found that about 50% of epithelial ovarian cancer patients have homologous recombination deficiency (HRD).